Asensus Surgical, Inc. (ASXC)
- Previous Close
0.2615 - Open
0.2800 - Bid 0.2550 x 1000
- Ask 0.2616 x 1400
- Day's Range
0.2555 - 0.2798 - 52 Week Range
0.2000 - 0.6500 - Volume
1,511,878 - Avg. Volume
1,597,806 - Market Cap (intraday)
70.806M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3000 - Earnings Date Aug 8, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
0.35
Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, the Middle East, Africa, and Asia. It digitizes the interface between the surgeon and the patient to perform performance-guided surgery for surgeons to deliver outcomes to patients. The company's products include Senhance System, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures; instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. is headquartered in Durham, North Carolina.
www.asensus.comRecent News: ASXC
Performance Overview: ASXC
Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ASXC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ASXC
Valuation Measures
Market Cap
70.81M
Enterprise Value
68.27M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.67
Price/Book (mrq)
5.44
Enterprise Value/Revenue
7.83
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-67.39%
Return on Equity (ttm)
-169.75%
Revenue (ttm)
8.72M
Net Income Avi to Common (ttm)
-78.71M
Diluted EPS (ttm)
-0.3000
Balance Sheet and Cash Flow
Total Cash (mrq)
7.99M
Total Debt/Equity (mrq)
41.89%
Levered Free Cash Flow (ttm)
-23.1M
Research Analysis: ASXC
Company Insights: ASXC
ASXC does not have Company Insights